Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative bioavailability and food-effect study of baricitinib tablets in healthy Japanese subjects
jRCT2080222636Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of baricitinib, sponsored by Eli Lilly and Company. Primary endpoints: Relative bioavailability of commercial vs Phase 2 baricitinib tablets and Effect of food on baricitinib commercial tablet bioavailability.
02
Drugs
baricitinib
Beyond the preview
Go deeper on jRCT2080222636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222636.